ArticleEClinicalMedicine2023

Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial.

Reiko Matsuzawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.